Author

M. A. Whitman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

A. A. Shimpi· 1 shared A. Chiou· 1 shared A. Varkaris· 1 shared A. Verma· 1 shared C. Fischbach· 1 shared D. J. Einstein· 1 shared F. Xie· 1 shared J. C. Patterson· 1 shared

Activity by Year

2022-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBioengineering

A. A. Shimpi

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Biofunctional matrix models reveal mineral-dependent mechanoregulation of bone metastatic breast cancer

S. Choi, M. A. Whitman, A. A. Shimpi, N. D. Sempertegui, A. Chiou, J. E. Druso, A. Verma, S. C. Lux, Z. Cheng, M. Paszek, O. Elemento, L. A. Estroff, C. Fischbach

The paper shows that mineralization in bone matrix models inhibits tumor cell proliferation and induces a stem-like phenotype, contradicting the assumption that rigidity promotes metastasis.

bioRxiv · Jun 29, 2022 · PreprintBioengineering

Polo-like kinase-1 Inhibitors and the Antiandrogen Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling

J. C. Patterson, A. Varkaris, P. J. P. Croucher, M. Ridinger, S. Darlymple, M. Nouri, F. Xie, S. Varmeh, O. Jonas, M. A. Whitman, S. Chen, S. Rashed, L. Makusha, J. Luo, J. T. Isaacs, , M. B. Yaffe

This study shows that combining Plk1 inhibitors with abiraterone synergistically kills cancer cells across tumor types, independent of androgen receptor signaling, through mitotic disruption.

bioRxiv · May 12, 2022 · PreprintCancer Biology